Globus Medical, Inc. (GMED)
USD 81.78
(-1.97%)
USD 81.78
(-1.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 122.87 Million USD | -35.39% |
| 2022 | 190.16 Million USD | 27.47% |
| 2021 | 149.19 Million USD | 45.86% |
| 2020 | 102.28 Million USD | -34.1% |
| 2019 | 155.21 Million USD | -0.81% |
| 2018 | 156.47 Million USD | 45.76% |
| 2017 | 107.34 Million USD | 2.88% |
| 2016 | 104.34 Million USD | -7.49% |
| 2015 | 112.78 Million USD | 21.95% |
| 2014 | 92.48 Million USD | 34.79% |
| 2013 | 68.61 Million USD | -7.07% |
| 2012 | 73.83 Million USD | 21.46% |
| 2011 | 60.78 Million USD | 11.62% |
| 2010 | 54.45 Million USD | 11.75% |
| 2009 | 48.73 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -7.11 Million USD | -147.34% |
| 2024 Q3 | 51.83 Million USD | 63.21% |
| 2024 Q2 | 31.76 Million USD | 546.26% |
| 2023 Q4 | 15.03 Million USD | 1406.41% |
| 2023 FY | 122.87 Million USD | -35.39% |
| 2023 Q1 | 49.12 Million USD | -1.87% |
| 2023 Q2 | 57.71 Million USD | 17.47% |
| 2023 Q3 | 998 Thousand USD | -98.27% |
| 2022 Q2 | 54.59 Million USD | 43.34% |
| 2022 Q4 | 50.06 Million USD | 5.55% |
| 2022 Q3 | 47.43 Million USD | -13.11% |
| 2022 FY | 190.16 Million USD | 27.47% |
| 2022 Q1 | 38.08 Million USD | 152.11% |
| 2021 Q2 | 41.54 Million USD | -8.35% |
| 2021 Q4 | 15.1 Million USD | -68.0% |
| 2021 FY | 149.19 Million USD | 45.86% |
| 2021 Q1 | 45.32 Million USD | -14.4% |
| 2021 Q3 | 47.21 Million USD | 13.64% |
| 2020 Q1 | 25.94 Million USD | -43.01% |
| 2020 FY | 102.28 Million USD | -34.1% |
| 2020 Q4 | 52.95 Million USD | 19.77% |
| 2020 Q3 | 44.21 Million USD | 312.2% |
| 2020 Q2 | -20.83 Million USD | -180.3% |
| 2019 Q3 | 38.3 Million USD | 0.38% |
| 2019 FY | 155.21 Million USD | -0.81% |
| 2019 Q1 | 33.21 Million USD | -9.63% |
| 2019 Q2 | 38.16 Million USD | 14.91% |
| 2019 Q4 | 45.52 Million USD | 18.85% |
| 2018 FY | 156.47 Million USD | 45.76% |
| 2018 Q4 | 36.75 Million USD | 4.38% |
| 2018 Q2 | 44.97 Million USD | 13.76% |
| 2018 Q1 | 39.53 Million USD | 62.2% |
| 2018 Q3 | 35.2 Million USD | -21.72% |
| 2017 Q1 | 28.71 Million USD | 18.17% |
| 2017 Q2 | 28.66 Million USD | -0.16% |
| 2017 Q3 | 25.59 Million USD | -10.73% |
| 2017 FY | 107.34 Million USD | 2.88% |
| 2017 Q4 | 24.37 Million USD | -4.75% |
| 2016 Q1 | 28.01 Million USD | -25.51% |
| 2016 Q3 | 26.22 Million USD | 1.63% |
| 2016 Q2 | 25.8 Million USD | -7.87% |
| 2016 Q4 | 24.29 Million USD | -7.36% |
| 2016 FY | 104.34 Million USD | -7.49% |
| 2015 Q1 | 24.64 Million USD | -10.82% |
| 2015 Q2 | 24.05 Million USD | -2.41% |
| 2015 Q3 | 26.48 Million USD | 10.09% |
| 2015 Q4 | 37.6 Million USD | 41.99% |
| 2015 FY | 112.78 Million USD | 21.95% |
| 2014 Q2 | 20.64 Million USD | -2.33% |
| 2014 Q4 | 27.63 Million USD | 19.85% |
| 2014 Q3 | 23.06 Million USD | 11.69% |
| 2014 Q1 | 21.13 Million USD | 0.73% |
| 2014 FY | 92.48 Million USD | 34.79% |
| 2013 FY | 68.61 Million USD | -7.07% |
| 2013 Q3 | 20.31 Million USD | 173.5% |
| 2013 Q4 | 20.98 Million USD | 3.32% |
| 2013 Q1 | 19.89 Million USD | -4.22% |
| 2013 Q2 | 7.42 Million USD | -62.67% |
| 2012 Q1 | 17.57 Million USD | 29.52% |
| 2012 FY | 73.83 Million USD | 21.46% |
| 2012 Q4 | 20.76 Million USD | 25.96% |
| 2012 Q3 | 16.48 Million USD | -13.23% |
| 2012 Q2 | 19 Million USD | 8.11% |
| 2011 Q4 | 13.57 Million USD | -19.53% |
| 2011 Q2 | 15.92 Million USD | 10.32% |
| 2011 FY | 60.78 Million USD | 11.62% |
| 2011 Q1 | 14.43 Million USD | 0.0% |
| 2011 Q3 | 16.86 Million USD | 5.92% |
| 2010 FY | 54.45 Million USD | 11.75% |
| 2009 FY | 48.73 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott Laboratories | 5.72 Billion USD | 97.853% |
| Allurion Technologies Inc. | -82.3 Million USD | 249.292% |
| Artivion, Inc. | -30.69 Million USD | 500.368% |
| Avanos Medical, Inc. | -61.8 Million USD | 298.824% |
| Butterfly Network, Inc. | -133.69 Million USD | 191.902% |
| Butterfly Network, Inc. | -133.69 Million USD | 191.902% |
| Bio-Rad Laboratories, Inc. | -637.32 Million USD | 119.28% |
| Boston Scientific Corporation | 1.59 Billion USD | 92.287% |
| Perspective Therapeutics, Inc. | -14.67 Million USD | 937.58% |
| CONMED Corporation | 64.45 Million USD | -90.622% |
| Edwards Lifesciences Corporation | 1.4 Billion USD | 91.238% |
| Paragon 28, Inc. | -47.84 Million USD | 356.836% |
| Glaukos Corporation | -134.66 Million USD | 191.246% |
| Inspire Medical Systems, Inc. | -21.15 Million USD | 680.877% |
| Integer Holdings Corporation | 90.65 Million USD | -35.547% |
| Medtronic plc | 3.67 Billion USD | 96.657% |
| Nevro Corp. | -92.21 Million USD | 233.249% |
| Owlet, Inc. | -32.9 Million USD | 473.463% |
| Penumbra, Inc. | 90.95 Million USD | -35.094% |
| Vicarious Surgical Inc. | -71.07 Million USD | 272.888% |
| Smith & Nephew plc | 263 Million USD | 53.28% |
| Sonendo, Inc. | -60.91 Million USD | 301.699% |
| STERIS plc | 378.23 Million USD | 67.514% |
| Stryker Corporation | 3.16 Billion USD | 96.118% |
| Vapotherm, Inc. | -58.19 Million USD | 311.147% |
| Zimmer Biomet Holdings, Inc. | 1.02 Billion USD | 88.001% |